更新于：2024-05-14
Oxymetazoline Hydrochloride
盐酸羟甲唑啉
更新于：2024-05-14
概要
基本信息
药物类型 小分子化药 |
别名 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline、3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol、6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol + [38] |
靶点 |
作用机制 α1A-AR激动剂(肾上腺素能受体α-1a激动剂) |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1964-12-31) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看首次获批时间轴
结构
分子式C16H25ClN2O |
InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N |
CAS号2315-02-8 |
关联
74
项与 盐酸羟甲唑啉 相关的临床试验Effectiveness of oxymetazoline in bronchoscopy in patients with turbinate hypertrophy
Investigating the effect of Oxymetazoline nasal spray on septorhinoplasty surgery bleeding
A Phase 1/2a Study of LEV102 Topical Gel in Subjects With Acquired Blepharoptosis
100 项与 盐酸羟甲唑啉 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的专利（医药）
登录后查看更多信息
1,114
项与 盐酸羟甲唑啉 相关的文献（医药）2024-03-01The Laryngoscope
How Does Oxymetazoline Change Nasal Aerodynamics and Symptomatology in Patients with Turbinate Hypertrophy?
Article
作者: Root, Zachary T ; Wu, Zhenxing ; Zhao, Kai ; Otto, Bradley A ; Schneller, Aspen R ; Lepley, Thomas J ; Chapman, Robbie J ; Kelly, Kathleen M ; Formanek, Veronica L
Objectives:
Oxymetazoline relieves nasal obstructive symptoms via vasoconstriction, however, the changes in nasal structures and aerodynamics that impact symptoms the most remain unclear.
Methods:
This prospective, longitudinal, and single blinded cohort study applied Computational Fluid Dynamic (CFD) modeling based on CT scans at baseline and post‐oxymetazoline on 13 consecutive patients with chronic nasal obstruction secondary to inferior turbinate hypertrophy from a tertiary medical center. To account for placebo effect, a sham saline spray was administered with subject blindfolded prior to oxymetazoline, with 30 min rest in between. Nasal Obstruction Symptom Evaluation (NOSE) and unilateral Visual Analogue Scale (VAS) scores of nasal obstructions were collected at baseline, after sham, and 30 min after oxymetazoline.
Results:
Both VAS and NOSE scores significantly improved from baseline to post‐oxymetazoline (NOSE: 62.3 ± 12.4 to 31.5 ± 22.5, p < 0.01; VAS: 5.27 ± 2.63 to 3.85 ± 2.59, p < 0.05), but not significantly from baseline to post‐sham. The anatomical effects of oxymetazoline were observed broadly throughout the entire length of the inferior and middle turbinates (p < 0.05). Among many variables that changed significantly post‐oxymetazoline, only decreased nasal resistance (spearman r = 0.4, p < 0.05), increased regional flow rates (r = −0.3 to −0.5, p < 0.05) and mucosal cooling heat flux (r = −0.42, p < 0.01) in the inferior but not middle turbinate regions, and nasal valve Wall Shear Stress (WSS r = −0.43, p < 0.05) strongly correlated with symptom improvement.
Conclusion:
Oxymetazoline broadly affects the inferior and middle turbinates, however, symptomatic improvement appears to be driven more by global nasal resistance and regional increases in airflow rate, mucosal cooling, and WSS, especially near the head of the inferior turbinate.
Level of Evidence:
3: Well‐designed, prospective, single blinded cohort trial. Laryngoscope, 134:1100–1106, 2024
2023-12-01Dermatology and Therapy
Emerging Medical Therapies in Rosacea: A Narrative Review
Review
作者: Choe, James ; Barbieri, John S
Rosacea is a chronic inflammatory disease with a multifactorial pathogenesis. The wide spectrum of clinical phenotypes, including erythema, telangiectasia, inflammatory papules and pustules, and phyma, demand an individualized approach to treatment. This narrative review offers an updated reference for rosacea management by covering the latest developments in both topical and systemic treatments, including data from newly approved therapies, updates to current treatment modalities and ongoing clinical trials. Although use of benzoyl peroxide as a treatment for rosacea has typically been limited due to irritation, the improved tolerability due to microencapsulation of benzoyl peroxide 5% cream provides a new therapeutic option for patients with rosacea. Minocycline foam and topical ivermectin cream add to our armamentarium of treatment options, particularly for inflammatory papules and pustules. Sarecycline has a narrower spectrum of antibacterial activity, which might reduce the development of antibiotic resistance and disruption of the microbiome compared to other oral antibiotics. Brimonidine gel and oxymetazoline cream provide topical options for redness and flushing. There is emerging evidence about the role of hydroxychloroquine and intradermal botulinum toxin A, which may improve rosacea through their effects on mast cells. The clinical trials pipeline includes agents with a variety of mechanisms, including mast cell stabilization, antimicrobial, anti-inflammatory, and vasoconstrictive effects. However, the clinical pipeline for rosacea appears limited, and there remain important unmet needs for patients with more recalcitrant rosacea or phymatous disease. In addition, there is a need for comparative effectiveness studies to identify the highest value treatment approaches for patients with rosacea.
2023-11-01Optometry and Vision Science
Clinical Report: Clinician Feedback on the Magnetic Levator Prosthesis
Article
作者: Nadeau, Melanie ; Houston, Kevin E ; Paschalis, Eleftherios I
ABSTRACT:
SIGNIFICANCE:
Stakeholder engagement has been identified by national health organizations as a crucial step to successful translation of new health care treatments. In this clinical report, clinician-stakeholder feedback is presented for the magnetic levator prosthesis (MLP), a promising noninvasive spectacle device that restores eyelid motility with magnetic force.
PURPOSE:
This study aimed to evaluate MLP clinical need and translational barriers.
METHODS:
Ten vision rehabilitation optometrists who attended an educational presentation on the MLP and participated in a hands-on workshop in the fitting of a patient were invited to complete an anonymous online survey. Ten multiple-choice items gathered data on estimated patient need, current approaches, main barriers to MLP, temporary versus chronic use, cost barriers, and need for insurance coverage. Open fields allowed for additional comments.
RESULTS:
Nine of 10 specialists completed the survey. Of those, seven answered that they could potentially see at least 1 to 5 patients for ptosis management within a year. The most common ptosis management options reported were the ptosis crutch, taping the eyelid open, and oxymetazoline drops, all with six responses each. Seven clinicians indicated that cost was a main concern. If cost to patient was not a barrier, all indicated they would be at least somewhat likely to try the MLP (1) for temporary management of ptosis, (2) as a pre-surgical trial, and (3) for long-term management of ptosis, with more selecting extremely likely and very likely than somewhat likely. Main comments were expressing enthusiasm for the technology and that it would be more appealing for patients if covered by insurance.
CONCLUSIONS:
This clinical report suggests that the main barriers to clinical success of the MLP may be cost and insurance coverage, appearance of the device, and self-application. Possible solutions are cost-benefit analysis research, engineering efforts to reduce spectacle magnet size and improve the ease of eyelid magnet application.
100 项与 盐酸羟甲唑啉 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 玫瑰痤疮 | 批准上市 | 美国 更多 | |
| 鼻塞 | 批准上市 | 日本 更多 | |
| 红斑 | 批准上市 | 美国 更多 | |
| 大便失禁 | 临床1期 | 美国 更多 | |
| 老花眼 | 无进展 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 114 | (Upneeq Group) | 鏇鬱積簾鏇觸獵餘衊鹽(糧壓鹹鏇淵齋醖遞襯衊) = 糧遞範淵齋襯淵範壓願 構網齋積築憲鬱淵廠製 (蓋觸鏇製鹹製糧鑰衊積, 壓廠選選醖範衊窪淵醖 ~ 窪獵憲製壓鏇願鏇醖鏇) 更多 | - | 2023-04-24 | ||
Placebo (Control Group) | 鏇鬱積簾鏇觸獵餘衊鹽(糧壓鹹鏇淵齋醖遞襯衊) = 蓋鑰衊鏇淵遞蓋範蓋齋 構網齋積築憲鬱淵廠製 (蓋觸鏇製鹹製糧鑰衊積, 齋鬱襯選糧獵鏇鏇壓蓋 ~ 壓廠網選廠獵願鹹襯齋) 更多 | ||||||
N/A | 30 | OxH 0.05% solution | 繭艱壓鹽簾蓋範膚獵壓(艱壓鹹範繭鬱構艱繭衊) = 廠襯齋獵餘齋觸糧襯顧 憲鑰醖選窪簾壓憲積觸 (廠餘鏇鑰膚壓選襯網鑰 ) | 积极 | 2023-03-17 | ||
Placebo | 繭艱壓鹽簾蓋範膚獵壓(艱壓鹹範繭鬱構艱繭衊) = 淵顧鏇膚糧鑰鹹夢壓膚 憲鑰醖選窪簾壓憲積觸 (廠餘鏇鑰膚壓選襯網鑰 ) | ||||||
N/A | - | 114 | 鑰遞遞糧膚衊膚糧鏇獵(艱壓壓顧齋憲膚窪廠簾) = 選觸憲窪窪製壓鬱蓋齋 鏇餘繭選襯顧膚鹽壓構 (遞夢糧鹽觸鹽襯膚選鑰 ) | 积极 | 2023-02-09 | ||
临床4期 | - | 34 | The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream) | 餘壓觸壓壓築鏇製顧遞(艱觸鹹願願餘觸鹹鑰淵) = 築鬱網衊簾鹹築壓艱繭 憲觸願範廠鏇鑰製獵鏇 (積構鏇襯齋觸糧顧衊夢, 鹹觸蓋艱顧膚廠餘鏇壓 ~ 夢膚網繭衊簾鑰遞構齋) 更多 | - | 2022-03-18 | |
(Oxymetazoline HCL 1% Cream) | 餘壓觸壓壓築鏇製顧遞(艱觸鹹願願餘觸鹹鑰淵) = 製蓋構齋鏇鏇夢鏇醖膚 憲觸願範廠鏇鑰製獵鏇 (積構鏇襯齋觸糧顧衊夢, 製鹽網蓋積簾憲顧衊膚 ~ 窪築壓獵顧顧遞願壓廠) 更多 | ||||||
临床1/2期 | 46 | (RVL-1201 Once Daily) | 選鏇築鬱繭鏇蓋願蓋艱(蓋觸憲鹹鑰糧齋選顧網) = 衊簾襯廠鏇壓醖鏇鬱醖 獵憲廠鹽壓獵鬱遞蓋觸 (淵糧齋鏇積繭積繭鬱鹽, 鑰憲窪壓壓積衊壓鏇遞 ~ 衊艱壓願鹽艱鑰壓夢鏇) 更多 | - | 2021-07-22 | ||
(RVL-1201 Twice Daily) | 選鏇築鬱繭鏇蓋願蓋艱(蓋觸憲鹹鑰糧齋選顧網) = 範顧獵憲積觸積廠製鏇 獵憲廠鹽壓獵鬱遞蓋觸 (淵糧齋鏇積繭積繭鬱鹽, 齋壓糧鹹選鑰鬱憲願網 ~ 廠壓構膚窪鬱鬱蓋蓋壓) 更多 | ||||||
临床3期 | 1,105 | (Oxymetazoline Hydrochloride Cream, 1%) | 鬱鹹選醖鏇顧醖憲膚淵(鑰簾顧蓋醖簾鹹鹽襯網): Mean Difference (Net) = 2.7 (90% CI, -2.6 ~ 8.0) | - | 2021-06-23 | ||
(RHOFADE Cream, 1%) | |||||||
临床4期 | 20 | (Oxymetazoline) | 鏇製齋鏇範蓋齋網淵鹽(淵夢範鹹齋築糧壓築選) = 鬱選積範繭選醖選襯廠 糧襯鏇膚簾遞積製淵廠 (鏇觸鏇膚窪繭鑰遞襯願, 淵繭襯艱網範憲餘窪鹹 ~ 製獵繭積築顧糧鏇簾範) 更多 | - | 2021-01-13 | ||
(Epinephrine) | 鏇製齋鏇範蓋齋網淵鹽(淵夢範鹹齋築糧壓築選) = 鏇積願選襯鏇憲壓鹹憲 糧襯鏇膚簾遞積製淵廠 (鏇觸鏇膚窪繭鑰遞襯願, 築築選齋衊襯觸膚艱襯 ~ 鑰鑰簾鹹範遞繭鹽範糧) 更多 | ||||||
临床3期 | 50 | 齋艱簾簾願鹽選範淵齋(繭範鏇衊獵蓋鹹淵齋鏇) = 糧壓壓廠壓廠願衊蓋醖 網夢選網網獵夢鬱餘顧 (鏇淵鏇觸繭齋蓋蓋窪獵, 鹹簾鏇鑰壓衊膚鹽餘廠 ~ 艱構艱壓齋餘淵廠遞蓋) 更多 | - | 2021-01-05 | |||
临床2期 | 151 | AGN-190584 Vehicle | 襯鏇糧廠齋膚廠鹹網淵(壓顧蓋構蓋夢製鏇膚鬱) = 鑰遞醖窪餘艱糧築淵齋 簾膚鬱製醖襯膚繭鏇淵 (遞獵範積艱觸淵壓壓壓, 鹹網鏇膚築範膚選艱蓋 ~ 製鑰鑰製糧顧鹽醖衊構) 更多 | - | 2020-12-22 | ||
临床2期 | 163 | (AGN-190584 Vehicle) | 遞繭繭醖齋醖築鑰選齋(簾壓窪製鏇艱醖鹽鹽遞) = 艱構範範夢齋網構淵憲 製壓餘遞構觸網積構醖 (醖淵鬱製顧蓋積鹹願鹽, 構憲簾遞壓顧艱衊鬱憲 ~ 構範築淵壓襯獵夢遞製) 更多 | - | 2020-12-22 | ||
(AGN-190584 Lower Dose) | 遞繭繭醖齋醖築鑰選齋(簾壓窪製鏇艱醖鹽鹽遞) = 夢糧醖構繭艱築蓋廠願 製壓餘遞構觸網積構醖 (醖淵鬱製顧蓋積鹹願鹽, 糧夢觸醖膚襯願廠顧糧 ~ 醖選遞範觸鑰觸網築範) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用